The role of gemcitabine in the treatment of malignant mesothelioma
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1) , 70-76
- https://doi.org/10.1053/sonc.2002.30232
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BLung Cancer, 2001
- Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)Lung Cancer, 2000
- New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 productionCancer Chemotherapy and Pharmacology, 2000
- In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agentsAnti-Cancer Drugs, 2000
- Carboplatin and Gemcitabine Chemotherapy for Malignant Pleural Mesothelioma: A Phase II Study of the GSTPVClinical Lung Cancer, 1999
- A phase II study of gemcitabine in patients with malignant pleural mesotheliomaCancer, 1999
- Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II StudyJournal of Clinical Oncology, 1999
- Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.Journal of Clinical Oncology, 1998
- Dihydro-5-azacytidine in malignant mesotheliomaCancer, 1997
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989